OS Therapies Announces Peer-Reviewed Publication Of Data From Its Phase 2 Clinical Trial Of OST-HER2 With Palliative Radiation Therapy To Prevent Amputation In Frontline Canine Osteosarcoma

OS Therapies Incorporated

OS Therapies Incorporated

OSTX

0.00

20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)

Over 15,000 dogs per year diagnosed with osteosarcoma

Company expects to submit U.S. Department of Agriculture meeting request to gain alignment on regulatory path towards conditional approval in the third quarter of 2026

OS Therapies reiterates plan to distribute OS Animal Health shares to shareholders

OS Animal Health plans crowdfunding to expand shareholder base to meet U.S. national exchange initial listing standards, with indications of interest now being received

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.